Schedule 13G ownership disclosure

Whitehawk Therapeutics, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 00032Q104

Event date: 2025-03-04

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ABG Management Ltd.

    Shares: 817,939.00 · Class: 1.8%

  • Ally Bridge Group (NY) LLC

    Shares: 817,939.00 · Class: 1.8%

  • Ally Bridge MedAlpha Master Fund L.P.

    Shares: 817,939.00 · Class: 1.8%

  • ABG Innovation Capital Partners III GP Limited

    Shares: 26,666.00 · Class: 0.1%

  • ABG Innovation Capital Partners III GP, L.P.

    Shares: 26,666.00 · Class: 0.1%

  • Ally Bridge Group Innovation Capital Partners III, L.P.

    Shares: 26,666.00 · Class: 0.1%

  • ABG Innovation-SO Limited

    Shares: 26,666.00 · Class: 0.1%

  • ABG Global Life Science Capital Partners V GP Limited

    Shares: 2,070,000.00 · Class: 4.5%

  • ABG Global Life Science Capital Partners V GP, L.P.

    Shares: 2,070,000.00 · Class: 4.5%

  • Ally Bridge Group Global Life Science Capital Partners V, L.P.

    Shares: 2,070,000.00 · Class: 4.5%

  • ABG-SIV, L.P.

    Shares: 2,070,000.00 · Class: 4.5%

  • ABG V-SIV Limited

    Shares: 2,070,000.00 · Class: 4.5%

  • Fan Yu

    Shares: 2,914,605.00 · Class: 6.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001493152-25-009710
Form type
SCHEDULE 13G
Filer
ABG Management Ltd.
CIK
CIK 1832106
Filed
Mar 10, 2025
Reporting period
Mar 04, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub